Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALX-0081 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| ALX-0081 | EXPERIMENTAL | - |
| GPIIb/IIIa inhibitor | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ALX-0081 | DRUG | 4 i.v. bolus injections, once every 6 hours; first dose of 6 mg, three subsequent doses of 4 mg |
| ReoPro® | DRUG | 0.25 mg/kg i.v. bolus injection followed by continuous i.v. infusion of 0.125 µg/kg/min (to a max. of 10 µg/min) for 12 hours |
Inclusion Criteria: * Have unstable angina or NSTEMI,or stable angina with at least 2 factors indicating a high risk PCI as follows: patient related: diabetic patients, renal failure (glomerular filtration rate \< 60), reduced left ventricular ejection fraction \< 35%, age \> 75 years, female gende...
ALX-0081 is an investigational small molecule being developed for unstable angina, a cardiovascular condition. It is also studied in patients with non-ST segment elevation myocardial infarction (NSTEMI) and stable angina associated with high-risk percutaneous coronary intervention (PCI). The drug is currently in Phase 2 clinical development.
ALX-0081 is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical trials to evaluate the safety and efficacy of ALX-0081 in cardiovascular indications.
ALX-0081 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The drug is being evaluated for use in unstable angina and related cardiovascular conditions.
ALX-0081 has one completed Phase 2 clinical trial with the identifier NCT01020383. This study compared ALX-0081 versus a GPIIb/IIIa inhibitor in high-risk percutaneous coronary intervention (PCI) patients. The trial enrolled 364 participants and was conducted in multiple countries including Austria, Belgium, Czechia, Germany, Israel, Poland, and Switzerland.
ALX-0081 is not known to have any alternative names. It is a unique investigational compound being developed by Sanofi. The drug is being studied under its current name in clinical trials for cardiovascular conditions.